Results 31 to 40 of about 12,486 (248)

Modelling and PBPK Simulation in Drug Discovery [PDF]

The AAPS Journal, 2009
Physiologically based pharmacokinetic (PBPK) models are composed of a series of differential equations and have been implemented in a number of commercial software packages. These models require species-specific and compound-specific input parameters and allow for the prediction of plasma and tissue concentration time profiles after intravenous and ...
Hannah M, Jones, Iain B, Gardner, Kenny J, Watson   +2 more
openaire   +2 more sources

Integration of Genome Scale Metabolic Networks and gene regulation of metabolic enzymes with Physiologically Based Pharmacokinetics [PDF]

, 2017
The scope of Physiologically Based Pharmacokinetic (PBPK) modelling can be expanded by assimilation of the mechanistic models of intracellular processes from Systems Biology field.
Al Olama, Alimirah, Arshad, Ay, Bailey, Beste, Blätke, Bordbar, Cannon, Covert, Covert, El-Sankary, Fell, Fisher, Giacomantonio, Gibson, Gille, Goss, Guebila, Heino, Huang, Huang, Huizenga, Jain, Jin, Jones, Kobayashi, Kolodkin, Kotas, Krauss, Lee, Lewis, Mark, Matsuno, Murata, Oakley, Orth, Pascussi, Plant, Reul, Schellenberger, Schilling, Schuster, Shmulevich, Steggles, Stephanopoulos, Varma, Watkins, Wienkers, Wu, Xiao, Zhang   +51 more
core   +2 more sources

Model reduction in mathematical pharmacology: integration, reduction and linking of PBPK and systems biology models [PDF]

, 2018
In this paper we present a framework for the reduction and linking of physiologically based pharmacokinetic (PBPK) models with models of systems biology to describe the effects of drug administration across multiple scales.
Snowden, Thomas J., Tindall, Marcus J., van der Graaf, Piet H.   +2 more
core   +1 more source

Physiologically based modeling and prediction of drug interactions [PDF]

, 2010
International audienceA major challenge for drug development and environmental or occupational health is the prediction of pharmacokinetic and pharmacodynamic interactions between drugs, natural chemicals or environmental contaminants.
Bois, Frédéric Y.
core   +3 more sources

Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction.

PLoS Computational Biology, 2016
Developing physiologically-based pharmacokinetic (PBPK) models for chemicals can be resource-intensive, as neither chemical-specific parameters nor in vivo pharmacokinetic data are easily available for model construction.
Jingtao Lu, Michael-Rock Goldsmith, Christopher M Grulke, Daniel T Chang, Raina D Brooks, Jeremy A Leonard, Martin B Phillips, Ethan D Hypes, Matthew J Fair, Rogelio Tornero-Velez, Jeffre Johnson, Curtis C Dary, Yu-Mei Tan   +12 more
doaj   +1 more source

Mechanistic Coupling of a Novel in silico Cotyledon Perfusion Model and a Physiologically Based Pharmacokinetic Model to Predict Fetal Acetaminophen Pharmacokinetics at Delivery

Frontiers in Pediatrics, 2021
Little is known about placental drug transfer and fetal pharmacokinetics despite increasing drug use in pregnant women. While physiologically based pharmacokinetic (PBPK) models can help in some cases to shed light on this knowledge gap, adequate ...
Paola Mian, Bridget Nolan, Bridget Nolan, John N. van den Anker, John N. van den Anker, Kristel van Calsteren, Kristel van Calsteren, Karel Allegaert, Karel Allegaert, Karel Allegaert, Nisha Lakhi, Nisha Lakhi, André Dallmann   +12 more
doaj   +1 more source

Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria [PDF]

, 2017
Majority of bioequivalence studies are conducted in healthy volunteers. It has been argued that bioequivalence may not necessarily hold true in relevant patient populations due to a variety of reasons which affect one formulation more than the other for ...
Darwich Adam S., Doki Kosuke, Patel Nikunjkumar, Rostami-Hodjegan Amin, 土岐 浩介   +4 more
core   +1 more source

Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report

CPT: Pharmacometrics & Systems Pharmacology, 2023
This report summarizes the proceedings for day 2 sessions 1 and 3 of the 2‐day public workshop entitled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” a jointly sponsored workshop by the US Food and Drug ...
Fang Wu, Youssef Mousa, Kimberly Raines, Chris Bode, Yu Chung Tsang, Rodrigo Cristofoletti, Hongling Zhang, Tycho Heimbach, Lanyan Fang, Filippos Kesisoglou, Amitava Mitra, James Polli, Myong‐Jin Kim, Jianghong Fan, Banu S. Zolnik, Duxin Sun, Yi Zhang, Liang Zhao   +17 more
doaj   +1 more source

PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals [PDF]

, 2010
International audienceGeneric PBPK models, applicable to a large number of substances, coupled to parameter databases and QSAR modules, are now available for predictive modelling of inter-individual variability in the absorption, distribution, metabolism
Bois, Frédéric Y., Clewell, Harvey J., Jamei, Massoud   +2 more
core   +3 more sources

Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer [PDF]

, 2013
The inhibitors of apoptosis proteins (IAPs) are a class of key apoptosis regulators overexpressed or dysregulated in cancer. SM‐406/AT‐406 is a potent and selective small molecule mimetic of Smac that antagonizes the inhibitor of apoptosis proteins (IAPs)
Baxter, Bissery, Brown, Cai, Cao, Chai, D'Argenio, Dai, Derendorf, Deveraux, Du, Hanahan, Holcik, Laufer, Liu, Lowe, Martinez-Ruiz, Nestorov, Nicholson, Norton, Ponder, Roth, Salphati, Salvesen, Shiozaki, Simeoni, Srinivasula, Verhagen, Wang, Xu, Yamazaki, Zhang   +31 more
core   +1 more source